

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takehi Y, Kamoto T, Shirai T, Ogawa O, Suzukamo Y, Fukuhara S, Saito Y, Tobisu K, Kakizoe T, Shibata T, Fukuda H, Akakura K, Suzuki H, Shinohara N, Egawa S, Irie A, Sato T, Maeda O, Meguro N, Sumiyoshi Y, Suzuki T, Shimizu N, Arai Y, Terai A, Kato T, Habuchi T, <u>Fujimoto H</u> , and Niwakawa M.	Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cNOMO prostate cancer.	Jpn. J. Clin. Oncol.	38	122-128	2008
Negishi T, and <u>Fujimoto H</u> .	A case of locally advanced prostate cancer in the transition zone.	Jpn. J. Clin. Oncol.	38	164	2008
Shintaku I, Satoh M, Okajima E, <u>Fujimoto H</u> , Kamoto T, Ogawa O, Kawai K, Akaza H, Tsukamoto T, Naito S, Miki T, and Arai Y.	Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan.	Jpn. J. Clin. Oncol.	38	281-287	2008
Kamidono S, Ohshima S, Hirao Y, Suzuki K, Arai Y, <u>Fujimoto H</u> , Egawa S, Akaza H, Hara I, Hinotsu S, Takehi Y, and Hasegawa T, Working Group for Creation of Clinical Practice Guidelines for Prostate Cancer, The Japanese Urological Association.	Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition).	Int. J. Urol.	15	1-18	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Miyake M, Sugano K, Kawashima K, Ichikawa H, Hirabayashi K, Kodama T, <u>Fujimoto H</u> , Kakizoe T, Kanai Y, Fujimoto K, Hirao Y.	Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping.	Biochem. Biophys. Res. Commun.	362	865-871	2007
Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, <u>Fujimoto H</u> , Fujiwara Y.	Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.	Eur. Urol.	52	1115-1122	2007
Kusters M, C.J.H. van de Velde, R.G.H. Beets-Tan, Akasu T, Fujita S, Yamamoto S, <u>Moriya Y.</u>	Patterns of local recurrence in rectal cancer: A single-center experience.	Ann Surg Oncol	16	289-296	2009
Ishiguro S, Yamamoto S, Fujita S, Akasu T, Kasters M, <u>Moriya Y.</u>	Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period.	Surgery	145 (2)	189-195	2009
Sakuraba M, Asano T, Yanoo T, Yamamoto S, <u>Moriya Y.</u>	Reconstruction of an enterocutaneous fistula using a superior gluteal artery perforator flap. (Case report)	An International Journal of Surgical Reconstruction (JPRAS)	62	108-111	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kusters M, Beets GL, van de Velde CJ, Beets-Tan RG, Marijnen CA, Rutten HJ, Putter H, <u>Moriya Y.</u>	A comparison between the treatment of low rectal cancer in Japan and the Netherlands, with focus on the patterns of local recurrence.	Annals of Surgery	249 (2)	229-235	2009
Akasu T, Sugihara K, <u>Moriya Y.</u>	Male urinary and sexual function after mesorectal excision alone or in combination with extended lateral pelvic lymph node dissection for rectal cancer.	Ann Surg Oncol	10	2779-2786	2009
<u>Moriya Y.</u>	Differences in rectal cancer surgery east versus west.	Lancet Oncol	10	1026-1027	2009
Fujita S, Yamamoto S, Akasu T, <u>Moriya Y.</u>	Risk factors of lateral pelvic lymph node metastasis in advanced rectal cancer.	Int J Colorectal Dis	24	1085-1090	2009
Akasu T, Yamaguchi T, Fujimoto Y, Ishiguro S, Yamamoto S, Fujita S, <u>Moriya Y.</u>	Abdominal sacral resection for posterior pelvic recurrence of rectal carcinoma: analyses of prognostic factors and recurrence patterns.	Ann Surg Oncol	14	74-83	2007
Uehara K, Shimoda T, Nakanishi Y, Taniguchi H, Akasu T, Fujita S, Yamamoto S, <u>Moriya Y.</u>	Clinicopathological significance of fibrous tissue around fixed recurrent rectal cancer in the pelvis.	Br J Surg	94	1530-1535	2007

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Uehara K, Nakanishi Y, Shimoda T, Taniguchi H, Akasu T, <u>Moriya Y.</u>	Clinicopathological significance of microscopic abscess formation at the invasive margin of advanced low rectal cancer.	Br J Surg	94	239-243	2007
Uehara M, Yamamoto S, Fujita S, Akasu T, <u>Moriya Y.</u> , Morisue A.	Isolated right external iliac lymph node recurrence from a primary cecum carcinoma: Report of a case.	Jpn J Clin Oncol	37(3)	230-232	2007
Nakajima T, Saito Y, Matsuda T, Hoshino T, Yamamoto S, <u>Moriya Y.</u> , Saito D.	Minute depressed-type submucosal invasive cancer; 5mm in diameter with intermediate lymph-node metastasis. Report of a Case.	Dis Colon Rectum	50	677-681	2007
Uehara K, Yamamoto S, Fujita S, Akasu T, <u>Moriya Y.</u>	Impact of Upward Lymph Node Dissection on Survival Rates in Advanced Lower Rectal Carcinoma.	Dig Surg	24(5)	375-381	2007
Ishibashi Y, Yamamoto S, Yamada Y, Fujita S, Akasu T, <u>Moriya Y.</u>	Laparoscopic resection for malignant lymphoma of the ileum causing ileocecal intussusception - Case Report-	Surg Laparosc Endosc Percutan Tech	17(15)	444-446	2007
Fujita S, Saito N, Yamada T, Takii Y, Kondo K, Ohue M, Ikeda E, <u>Moriya Y.</u>	Randomized, Multicenter Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery.	Arch Surg	142	657-661	2007
Fujita S, Yamamoto S, Akasu T, <u>Moriya Y.</u> , Taniguchi H, Shimoda T.	Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis.	Anticancer Research	27	3307-3312	2007
Terauchi T, Tateishi U, Maeda T, Kanou D, Daisaki H, <u>Moriya Y.</u> , Moriyama N, Kakizoe T.	A case of colon cancer detected by carbon-11 choline positron emission tomography/ computed tomography: An initial report.	Jpn J Clin Oncol	37(10)	797-800	2007


発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamamoto S, Fujita S, Akasu T, Ishiguro S, Kobayashi Y, <u>Moriya Y.</u>	Wound infection after elective laparoscopic surgery for colorectal carcinoma.	Surg Endosc	21	2248-2252	2007
Fujita S, Nakanishi Y, Taniguchi H, Yamamoto S, Akasu T, <u>Moriya Y.</u> , Shimoda T.	Cancer invasion to Auerbach's plexus is an important prognostic factor in patients with pT3-pT4 colorectal cancer.	Dis Colon Rectum	50	1860-1866	2007
Nakagohri T, <u>Kinoshita T.</u> , Konishi M, Takahashi S, Gotohda N, Kobayashi S, Kojima M, Miyauchi H, and Asano T	Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.	J. Hepatobiliary. Pancreat. Surg.			[Epub ahead of print]
Fujita T, Nakagohri T, Gotohda N, Takahashi S, Konishi M, Kojima M, and <u>Kinoshita T</u>	Evaluation of the Prognostic Factors and Significance of Lymph Node Status in Invasive Ductal Carcinoma of the Body or Tail of the Pancreas.	Pancreas			[Epub ahead of print]
Fujita T, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Ochiai A, and <u>Kinoshita T</u>	Incidence, clinical presentation and pathological features of benign sclerosing cholangitis of unknown origin masquerading as biliary carcinoma.	J. Hepatobiliary. Pancreat. Surg.			[Epub ahead of print]
Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, <u>Kinoshita T.</u> and Nakatsura T	Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.	Cancer Sci	100	1403-1407	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, <u>Kinoshita T</u> , and Nakatsura T	Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.	Int. J. Oncol	34	649-656	2009
Kobayashi S, Gotohda N, Nakagohri T, Takahashi S, Konishi M, and <u>Kinoshita T</u>	Risk factors of surgical site infection after hepatectomy for liver cancers.	World J. Surg.	33	312-317	2009
<u>Kinoshita T</u> , Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, Miyashiro I, Kaji M, and Ninomiya M	Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002).	Gastric Cancer	12	37-42	2009
Hirayama A, Kami K, Sugimoto M, Sugawara M, Tokinaka N, Onozuka H, <u>Kinoshita T</u> , Saito N, Ochiai A, Tomita M, Esumi H, and Soga T	Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry.	Cancer Res.	69	4918-4925	2009
Fujita T, Gotohda N, Takahashi S, Nakagohri T, Konishi M, and <u>Kinoshita T</u>	Clinical and histopathological features of remnant gastric cancers, after gastrectomy for synchronous multiple gastric cancers.	J. Surg. Oncol.	100	466-471	2009
Nobuoka D, Gotohda N, Konishi M, Nakagohri T, Takahashi S, <u>Kinoshita T</u> .	Prevention of postoperative pancreatic fistula after total gastrectomy.	World J. Surg.	32	2261-2266	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Mitsunaga S, <u>Kinoshita T</u> , Hasebe T, Nakagohri T, Konishi M, Takahashi S, Gotohda N, Ochiai A.	Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.	Pancreas.	36	241-248	2008
Kajiwarara M, Kojima M, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Hasebe T, Ochiai A, <u>Kinoshita T</u> .	Autoimmune pancreatitis with multifocal lesions.	J. Hepatobiliary Pancreat. Surg.	15	449-452	2008
Kajiwarara M, Gotohda N, Konishi M, Nakagohri T, Takahashi S, Kojima M, <u>Kinoshita T</u> .	Incidence of the focal type of autoimmune pancreatitis in chronic pancreatitis suspected to be pancreatic carcinoma: experience of a single tertiary cancer center.	Scand. J. Gastroenterol.	43	110-116	2008
Hasebe T, Konishi M, Iwasaki M, Nakagohri T, Takahashi A, Gotohda N, <u>Kinoshita T</u> , Ochiai A.	Primary tumor/vessel tumor/nodal tumor classification of extrahepatic bile duct carcinoma.	Hum. Pathol.	39	37-48	2008
Nakagohri, T., <u>Kinoshita T.</u> , Konishi, M., Takahashi, S., Tanizawa, Y.	Clinical Results of Extended Lymphadenectomy and Intraoperative Radiotherapy for Pancreatic Adenocarcinoma.	Hepato-Gastroenterology	54(74)	564-569	2007
Nakagohri, T., <u>Kinoshita T.</u> , Konishi, M., Takahashi, S., and Gotohda, N.	Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas.	Ann Surg Oncol	14(11)	3174-3180	2007
Mitsunaga, S., Hasebe, T., <u>Kinoshita T.</u> , Konishi, M., Takahashi, S., Gotohda, N., Nakagohri, T., and Ochiai, A.	Detail Histologic Analysis of Nerve Plexus Invasion in Invasive Ductal Carcinoma of the Pancreas and Its Prognostic Impact.	Am J Surg Pathol	11(31)	1636-1644	2007
Kajiwarara, M., Fujii, S., Takahashi, S., Konishi, M., Nakagohri, T., Gotohda, N., and <u>Kinoshita T.</u>	Adenocarcinoma of the minor duodenal papilla with intraepithelial spread to the pancreatic duct.	Virchows Arch	451	1075-1081	2007

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kajiwara, M., Gotohda, N., Konishi, M., Nakagohri, T., Takahashi, S., Kojima, M., Hasebe, T., and <u>Kinoshita, T.</u>	Cystic endocrine tumor of the pancreas with an atypical multilocular appearance.	J Hepatobiliary Pancreat Surg	14	586-589	2007
<u>Sano T.</u>	Adjuvant and neoadjuvant therapy of gastric cancer: a comparison of three pivotal studies.	Current Oncol. Rep.	10	191-198	2008
Sasako M, <u>Sano T</u> , Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, <u>Kinoshita T</u> , Arai K, Yamamura Y, Okajima K: Japan Clinical Oncology Group.	D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.	N. Engl. J. Med	359	453-462	2008
Morita S, Katai H, Saka M, Fukagawa T, <u>Sano T</u> , Sasako M.	Outcome of pylorus-preserving gastrectomy for early gastric cancer.	Br. J. Surg.	95	1131-1135	2008
Oda I, Gotoda T Sasako M, <u>Sano T</u> , Katai H, Fukagawa T, Shimoda T, Emura F, Saito D.	Treatment strategy after non-curative endoscopic resection of early gastric cancer.	Br. J. Surg.	95	1495-1500	2008
Nunobe S, <u>Sano T.</u>	Symptom evaluation of long-term postoperative outcomes after pylorus-preserving gastrectomy for early gastric cancer.	Gastric Cancer	10	167-172	2007
Kosaka Y, <u>Sano T.</u>	Identification of the high-risk group for metastasis of gastric cancer cases by vascular endothelial growth factor receptor-I overexpression in peripheral blood.	British J Cancer	96	1723-1728	2007
<u>Sano T.</u>	Tailoring treatments for curable gastric cancer.	Br J Surg	94	263-264	2007

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sasako M, <u>Sano T.</u>	Surgical treatment of advanced gastric cancer: Japanese perspective.	Dig Surg	24	101-107	2007
Tsujinaka T, <u>Sano T.</u>	Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501).	Ann Surg Oncol	14	355-361	2007



Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer

Young Hak Kim^{a,b,c}, Genichiro Ishii^a, Koichi Goto^b, Shuji Ota^{a,b}, Kaoru Kubota^b, Yukinori Murata^a, Michiaki Mishima^c, Nagahiro Saijo^b, Yutaka Nishiwaki^b, Atsushi Ochiai^{a,*}

^a Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan

^b Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan

^c Department of Respiratory Medicine, Kyoto University Hospital, Kyoto, Japan

ARTICLE INFO

Article history:

Received 21 February 2008

Received in revised form 19 May 2008

Accepted 4 October 2008

Keywords:

SCLC

MDR

ABC transporter

DNA excision repair

BCRP

ABSTRACT

Background: ATP-binding cassette (ABC) transporter and DNA excision repair proteins play a pivotal role in the mechanisms of drug resistance. The aim of this study was to investigate the expression of ABC transporter and DNA excision repair proteins, and to elucidate the clinical significance of their expression in biopsy specimens from patients with small-cell lung cancer (SCLC).

Methods: We investigated expression of the ABC transporter proteins, P-glycoprotein (Pgp), multidrug resistance associated-protein 1 (MRP1), MRP2, MRP3, and breast cancer resistance protein (BCRP), and the DNA excision repair proteins, excision repair cross-complementation group 1 (ERCC1) protein and breast cancer susceptibility gene 1 (BRCA1) protein, in tumor biopsy specimens obtained before chemotherapy from 130 SCLC patients who later received platinum-based combination chemotherapy, and investigated the relationship between their expression and both response and survival.

Results: No significant associations were found between expression of Pgp, MRP1, MRP2, MRP3, ERCC1, or BRCA1 and either response or survival. However, there was a significant association between BCRP expression and both response ($p=0.026$) and progression-free survival (PFS; $p=0.0103$).

Conclusions: BCRP expression was significantly predictive of both response and progression-free survival (PFS) in SCLC patients receiving chemotherapy. These findings suggest that BCRP may play a crucial role in drug resistance mechanisms, and that it may serve as an ideal molecular target for the treatment of SCLC.

© 2008 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Lung cancer is the leading cause of cancer-related deaths in many industrialized countries. Although the proportion of patients with small-cell lung cancer (SCLC) has been decreasing, it still accounts for approximately 15% of all cases of lung cancer. SCLC is one of the most chemo-sensitive solid tumors, but the vast majority of patients eventually experience a relapse, and as a result the median survival time is 14–20 months for limited disease (LD) and 7–10 months for extensive disease (ED) [1].

Intrinsic or acquired drug resistance is considered to be a major factor limiting the effectiveness of chemotherapy. Drug resistance by tumors occurs not only to a single cytotoxic agent, but in the form of cross-resistance to other cytotoxic agents, called multidrug resistance (MDR). One of the major mechanisms of MDR

is increased ability of tumor cells to actively efflux drugs, which leads to a decrease in intracellular drug accumulation, and the mechanism is mediated by ATP-dependent drug efflux pumps that are known as ATP-binding cassette (ABC) transporters [2,3]. To date, at least 48 human ABC transporters have been identified, and they have been divided into seven subfamilies, ABC-A through ABC-G. Five of them, P-glycoprotein (Pgp), multidrug resistance associated-protein 1 (MRP1), MRP2, MRP3, and breast cancer resistance protein (BCRP), have been most intensively investigated, and *in vitro* studies have demonstrated associations between their expression and resistance to cytotoxic drugs commonly used in the treatment of SCLC, including etoposide, irinotecan, and topotecan [4].

Another important mechanism of drug resistance is increased repair of DNA damage mediated by the DNA excision repair gene. Resistance to platinum is associated with increased removal of platinum-DNA adducts, and DNA excision repair plays a pivotal role in this process [5]. Nucleotide excision repair (NER) is a major mechanism for repairing platinum-DNA adducts, and it is

* Corresponding author. Tel.: +81 4 7134 6855; fax: +81 4 7134 6865.
E-mail address: aochiai@east.ncc.go.jp (A. Ochiai).

Table 1
Panel of primary antibodies.

Antibody	Clone	Pretreatment	Dilution	City/nation	Source
Pgp (mono)	JSB-1	Autoclave	1:20	Newcastle/United Kingdom	Novocastra
MRP1 (mono)	MRPm6	Autoclave	1:50	Uden/Netherlands	Sanbio
MRP2 (mono)	M2III-6	Autoclave	1:20	Uden/Netherlands	Sanbio
MRP3 (mono)	DTX1	Autoclave	1:100	Newcastle/United Kingdom	Novocastra
BCRP (mono)	BXP21	Autoclave	1:20	Uden/Netherlands	Sanbio
ERCC1 (mono)	8F1	Autoclave	1:100	Warm Springs/United States	Lab vision
BRCA1 (mono)	MS110	Microwave	1:100	San Diego/United States	Carbiochem

now known that there are two pathways in NER: transcription-coupled NER (TC-NER) and global genomic NER (GG-NER) [5]. Among NER proteins, excision repair cross-complementation group 1 (ERCC1) protein, which is involved in the GG-NER pathway, has been most intensively investigated. Expression of ERCC1 has recently been shown to be a significant negative predictive factor for survival of non-small cell lung cancer (NSCLC) patients receiving cisplatin-based adjuvant chemotherapy [6]. On the other hand, the results of an *in vitro* study have suggested the superiority of TC-NER pathway, in which breast cancer susceptibility gene 1 (BRCA1) protein is involved, to GG-NER pathway in predicting platinum resistance [7]. Since platinum agents are considered to be key drugs in the treatment of SCLC as well as NSCLC [8–10], it is of great interest to determine whether there is an association between the expression of DNA excision repair genes and the effectiveness of platinum-based chemotherapy in SCLC patients.

In this retrospective study we investigated the immunohistochemical expression of the ABC transporter proteins, Pgp, MRP1, MRP2, MRP3, and BCRP, and the DNA excision repair proteins, ERCC1 protein and BRCA1 protein, in tumor biopsy specimens obtained before chemotherapy from 130 SCLC patients who later received platinum-based combination chemotherapy, and we investigated the relationship between their expression and the patients' clinical outcome.

2. Materials and methods

2.1. Subjects

A total of 626 patients were diagnosed with SCLC at the National Cancer Center Hospital East between July 1992 and December 2005, and 578 of them received platinum-based combination chemotherapy as an initial treatment. After excluding the 246 patients who received thoracic radiotherapy and 2 patients who received surgery in order to eliminate the effects of treatment other than chemotherapy, the 191 patients of the remaining 330 patients diagnosed only cytologically, and therefore with no specimens available for analysis, and the nine patients whose specimens were unsuitable for immunohistochemistry. In this study, we analyzed biopsy specimens from 130 patients consisting of 104 responders and 26 non-responders. Institutional Review Board-approved informed consent was obtained from all patients.

2.2. Clinical evaluation

The classification system proposed by the Veterans' Administration Lung Study Group was used to stage SCLC as limited disease (LD) or extensive disease (ED) [11]. LD is defined as disease confined to one hemithorax that can be encompassed within a single radiation field, and ED is defined as disease that extends beyond these confines. Performance status (PS) was determined based on the Eastern Cooperative Oncology Group (ECOG) scale. Patient response

was evaluated by using the Response Evaluation Criteria in Solid Tumors (RECIST) [12].

2.3. Immunohistochemistry

Tissue blocks were cut into 4- μ m sections and mounted on silane-coated slides (Matsunami, Tokyo, Japan). The slides were then deparaffinized in xylene and dehydrated in a graded alcohol series. For antigen retrieval, the slides for Pgp, MRP1, MRP2, BCRP, ERCC1, and BRCA1 were immersed in 10 mM citric buffer solution (pH 6.0) at 120 °C for 20 min and the slides for MRP3 were immersed in 1 mM EDTA retrieval fluid (pH 8.0) at 95 °C for 20 min. The slides were then allowed to cool for 1 h at room temperature and washed in PBS. Nonspecific binding was blocked by incubation with 2% BSA plus 0.1% Na₂S₂O₃ for 30 min, and after draining off the blocking solution, the slides were incubated overnight at 4 °C with the primary antibodies listed in Table 1. Endogenous peroxidase was then blocked with 0.3% H₂O₂ in methanol for 10 min, and after washing three times in PBS, the slides were incubated for 60 min with a labeled polymer En Vision+, peroxidase Mouse (DAKO, Glostrup, Denmark). The chromogen used was 2% 3,3'-diaminobenzidine in 50 mM Tris buffer (pH 7.6) containing 0.3% hydrogen, and the slides were counterstained with hematoxylin. Normal human liver tissue was used as a positive control for Pgp, MRP2, MRP3, and BCRP, normal human lung tissue for MRP1, normal human tonsil tissue for ERCC1, and breast cancer tissue human for BRCA1. Negative controls for each antibody were prepared by using non-immune serum instead of the primary antibodies. Membranous or cytoplasmic staining was evaluated for ABC transporter proteins [13], while nuclear staining was evaluated for DNA excision repair proteins [6,14]. Staining of each antibody was considered positive if >10% of the tumor cells stained. All of the slides were examined and scored independently by two observers (Y.K. and G.I.) without knowledge of the patients' clinical data. When judgments differed between two observers, they discussed it until an agreement was reached.

2.4. Statistical analysis

The significance of the relationship between immunohistochemical expression and clinical variables or response to chemotherapy was evaluated by using the χ^2 test or Fisher's exact test, as appropriate. The logistic regression model was used for multivariate analysis of response. Progression-free survival (PFS) was used as a clinical marker for duration of response to chemotherapy. Overall survival (OS) was measured from the start of chemotherapy to the date of death from any cause or the date patients were last known to be alive. Survival rates were calculated by the Kaplan–Meier method, and the statistical significance of any differences in PFS and OS were evaluated by a log-rank test. The Cox proportional hazards model was used for multivariate analysis of survival. *p* values less than 0.05 were considered significant. All statistical analyses were performed using

Table 2
Patient characteristics (n = 130).

Characteristics	No. of patients (%)
Age	
Median	67
Range	28–83
Gender	
Male	108 (83)
Female	22 (17)
Disease extent	
LD	18 (14)
ED	112 (86)
Performance status	
0	2 (2)
1	93 (71)
2	25 (19)
3	8 (6)
4	2 (2)
Chemotherapy regimen	
CE	36 (28)
PE	35 (27)
PI	25 (19)
CODE	18 (14)
CAV/PE	7 (5)
PEI	7 (5)
PT	2 (2)

LD, limited disease; ED, extensive disease; CE, Carboplatin + Etoposide; PE, Cisplatin + Etoposide; PI, Cisplatin + Irinotecan; CODE, Cisplatin + Vincristine + Doxorubicin + Etoposide; CAV/PE, Cyclophosphamide + Doxorubicin + Vincristine/Cisplatin + Etoposide; PEI, Cisplatin + Etoposide + Irinotecan; PT, Cisplatin + Topotecan.

the statistical program StatView, Version 5.0 (Abacus Concepts, Berkeley, CA).

3. Results

3.1. Patient characteristics

The patient characteristics are summarized in Table 2. The median age of the patients was 67 years (range: 28–83 years). More than 80% of the patients were male, and more than 80% had ED. Despite excluding patients who had received thoracic radiotherapy or surgery, our study included 18 LD patients. The major reasons

for omitting thoracic radiotherapy in these LD patients were the presence of a malignant pleural effusion (9 patients) and interstitial pneumonia (5 patients). PS was generally good; approximately 70% of the patients were PS 0 or 1. All patients received chemotherapy containing etoposide, irinotecan, or topotecan. The details of administered chemotherapy are shown in Table 3.

3.2. Expression of ABC transporter and DNA excision repair proteins in SCLC

The immunostaining of ABC transporter proteins was both membranous and cytoplasmic, whereas the immunostaining of the DNA excision repair proteins was mostly restricted to the nucleus. Forty-two (33%) of the 130 tumors were Pgp-positive, 29 (22%) were MRP1-positive, 25 (19%) were MRP2-positive, 9 (7%) were MRP3-positive, 48 (37%) were BCRP-positive, 36 (27%) were ERCC1-positive, and 109 (83%) were BRCA1-positive. The relationships between expression of the ABC transporter and DNA excision repair proteins and the clinical variables are shown in Table 4. BCRP expression was significantly greater in the PS 2–4 cases than in the PS 0–1 cases ($p=0.0223$). There were no significant correlations between expression of Pgp, MRP1, MRP2, MRP3, ERCC1, or BRCA1 and the clinical variables.

3.3. Association between expression of ABC transporter and DNA excision repair proteins and clinical outcome

The relationships between clinical variables and response to chemotherapy and survival are shown in Table 5. Response rate was not associated with any clinical variables, but PFS ($p=0.0199$) and OS ($p=0.0159$) were significantly associated with PS. Table 6 shows the associations between expression of ABC transporter and DNA excision repair proteins and response to chemotherapy and survival. BCRP expression was significantly predictive of response to chemotherapy ($p=0.026$), and MRP2 expression was marginally predictive ($p=0.0515$).

The median follow-up time was 8.3 years, and 119 patients had been dead until the time of analysis. The results for survival showed that BCRP expression was significantly associated with PFS ($p=0.0103$), but not with OS ($p=0.1427$). No significant associations were observed between expression of Pgp, MRP1, MRP3, ERCC1, or

Table 3
Details of administered chemotherapy.

Regimen	Dosage of each agent	Schedule	Median number of treatment cycles (range)
CE	Carboplatin	AUC 6	Day 1
	Etoposide	100 mg/m ²	Days 1–3
PE	Cisplatin	60 mg/m ²	Day 1
	Etoposide	100 mg/m ²	Days 1–3
PI	Cisplatin	60 mg/m ²	Day 1
	Irinotecan	60 mg/m ²	Days 1, 8, 15
CODE	Cisplatin	25 mg/m ²	Day 1 (1, 2, 3, 4, 5, 6, 7, 8, 9 weeks)
	Vincristine	1 mg/m ²	Day 1 (2, 4, 6, 8 weeks)
	Doxorubicin	40 mg/m ²	Day 1 (1, 3, 5, 7 weeks)
CAV/PE	Etoposide	80 mg/m ²	Day 1–3 (1, 3, 5, 7 weeks)
	Cyclophosphamide	800 mg/m ²	Day 1
	Doxorubicin	50 mg/m ²	Day 1
	Vincristine	1.4 mg/m ²	Day 1
PEI	Cisplatin	80 mg/m ²	Day 1
	Etoposide	100 mg/m ²	Day 1, 3, 5
	Cisplatin	25 mg/m ²	Day 1 (1, 2, 3, 4, 5, 6, 7, 8, 9 weeks)
PT	Etoposide	60 mg/m ²	Days 1–3 (1, 3, 5, 7 weeks)
	Irinotecan	90 mg/m ²	Day 1 (2, 4, 6, 8 weeks)
	Cisplatin	60 mg/m ²	Day 5
	Topotecan	1 mg/m ²	Days 1–5

AUC, area under the curve.

Table 4
Relationship between clinical variables and expression of ABC transporter and DNA excision repair proteins.

	n	Pgp-positive (%)	MRP1-positive (%)	MRP2-positive (%)	MRP3-positive (%)	BCRP-positive (%)	ERCC1-positive (%)	BRCA1-positive (%)
Total	130	42 (33)	29 (22)	25 (19)	9 (7)	48 (37)	36 (27)	109 (83)
Age								
<70	83	29 (35)	16 (19)	15 (18)	5 (6)	29 (35)	24 (29)	70 (84)
≥70	47	13 (28)	13 (28)	10 (21)	4 (9)	19 (40)	12 (26)	39 (83)
Gender								
Male	108	36 (33)	23 (21)	19 (18)	9 (8)	41 (38)	30 (28)	93 (86)
Female	22	6 (27)	6 (27)	6 (27)	0 (0)	7 (32)	6 (27)	16 (73)
Disease extent								
LD	18	8 (44)	3 (17)	6 (33)	3 (17)	8 (44)	4 (22)	16 (89)
ED	112	34 (30)	26 (23)	19 (17)	6 (5)	40 (36)	32 (29)	93 (83)
PS								
0–1	95	33 (35)	20 (21)	21 (22)	8 (8)	29 (31) ^a	27 (28)	80 (84)
2–4	35	9 (26)	9 (26)	4 (11)	1 (3)	19 (54)	9 (26)	29 (83)

ABC, ATP-binding cassette; Pgp, P-glycoprotein; MRP, multidrug resistance protein; BCRP, breast cancer resistance protein; ERCC, excision repair cross-complementation group; BRCA, breast cancer susceptibility gene; LD, limited disease; ED, extensive disease; PS, performance status.

^a $p=0.0223$.

Table 5
Summary of relationship between clinical variables and response to chemotherapy and survival.

	n	Response rate (%)	p	PFS (mo)	p	MST (mo)	p
Total	130	79		5.2		9.0	
Age							
<70	83	80	>0.9999	5.1	0.1296	9.4	0.3493
≥70	47	81		5.4		10.9	
Gender							
Male	108	81	0.7715	5.1	0.5496	9.4	0.6528
Female	22	77		5.7		13.2	
Disease extent							
LD	18	67	0.2277	5.6	0.4838	9.4	0.8856
ED	112	82		5.2		10.4	
PS							
0–1	95	82	0.4584	5.5	0.0199 [*]	10.8	0.0159 [*]
2–4	35	74		4.2		8.1	

LD, limited disease; ED, extensive disease; PS, performance status; PFS, progression-free survival; MST, median survival time.

^{*} $p<0.05$.

Table 6
Association between expression of ABC transporter and DNA excision repair proteins and response to chemotherapy and survival (n = 130).

	n	Response rate (%)	p	PFS (mo)	p	MST (mo)	p
Pgp							
Positive	42	83	0.6730	5.5	0.7257	10.5	0.3006
Negative	88	78		5.1		9.9	
MRP1							
Positive	29	90	0.1902	5.3	0.8141	11.0	0.2249
Negative	101	77		5.2		9.4	
MRP2							
Positive	25	64	0.0515	5.6	0.5832	12.6	0.1261
Negative	105	84		5.2		9.3	
MRP3							
Positive	9	78	>0.9999	5.2	0.3181	11.9	0.1326
Negative	121	80		5.3		9.4	
BCRP							
Positive	48	69	0.0260 [*]	4.0	0.0103 [*]	9.1	0.1427
Negative	82	87		5.6		10.6	
ERCC1							
Positive	36	89	0.1452	5.4	0.5383	11.9	0.6250
Negative	94	77		4.3		9.3	
BRCA1							
Positive	109	79	0.5666	5.3	0.8404	10.5	0.4611
Negative	21	86		4.7		8.1	

ABC, ATP-binding cassette; Pgp, P-glycoprotein; MRP, multidrug resistance protein; BCRP, breast cancer resistance protein; ERCC, excision repair cross-complementation group; BRCA, breast cancer susceptibility gene; PFS, progression-free survival; MST, median survival time.

^{*} $p<0.05$.




Fig. 1. Representative cases of positive immunostaining for BCRP (A, $\times 100$; B, $\times 400$) and MRP2 (C, $\times 100$; D, $\times 400$). BCRP and MRP2 in the apical membrane of the bronchial layer have been immunostained as a positive control.

BRCA1 and either response to chemotherapy or survival. Representative immunohistochemical staining of BCRP and MRP2 is shown in Fig. 1.

3.4. Multivariate analysis for response and survival

A multivariate analysis revealed that BCRP expression was significantly predictive of response to chemotherapy (Table 7). PFS was significantly associated with both PS ($p = 0.0299$) and BCRP expression ($p = 0.0138$), whereas OS was significantly associated with PS alone ($p = 0.0295$; Table 8). The PFS and OS curves according to BCRP expression are shown in Fig. 2.

4. Discussion

Although initial chemotherapy succeeds in 80–90% of SCLC patients, most patients eventually experience a relapse and their survival time is quite limited. Unfortunately, little progress in the chemotherapy of SCLC has been made during the past 30 years [15]. If drug resistance could be overcome, it would no doubt lead to an improved prognosis of this challenging disease, because drug

resistance is considered a major obstacle to successful treatment. In this study we investigated expression of the five ABC transporter proteins that are thought to be the most important in the drug resistance mechanisms of SCLC, and the results showed that BCRP expression alone was significantly associated with either response to chemotherapy or PFS. Expression of BCRP was significantly correlated with impaired PS, but the multivariate analysis revealed BCRP to be an independent prognostic factor for PFS.

BCRP, which is classified as ABCG2 and known as the mitoxantrone resistance gene (MXR) or ABC transporter in placenta (ABC-P), is expressed in a variety of normal tissues, with the highest levels having been found in the placenta, and lower levels in the liver, small intestine, brain, and ducts and lobules of the breast [2,16]. BCRP was initially isolated from doxorubicin-resistant breast

Table 7
Multivariate analysis for response ($n = 130$).

Variables	Category	Risk ratio	95% CI	<i>p</i>
Age	<70 vs. ≥ 70	0.701	0.263–1.869	0.4776
Gender	Female vs. Male	0.857	0.258–2.848	0.8014
Disease extent	LD vs. ED	1.81	0.545–6.018	0.3329
PS	0–1 vs. 2–4	1.315	0.471–3.676	0.6013
MRP2	(–) vs. (+)	2.238	0.779–6.429	0.1346
BCRP	(–) vs. (+)	2.804	1.103–7.128	0.0303

^{*} $p < 0.05$.

Table 8
Multivariate analysis for survival ($n = 130$).

Variables	Category	Risk ratio	95% CI	<i>p</i>
A. Progression-free survival				
Age	<70 vs. ≥ 70	0.691	0.464–1.028	0.0682
Gender	Female vs. Male	1.062	0.650–1.733	0.8105
Disease extent	LD vs. ED	0.87	0.501–1.512	0.6251
PS	0–1 vs. 2–4	1.592	1.046–2.424	0.0299 [*]
BCRP	(–) vs. (+)	1.614	1.102–2.363	0.0138 [*]
B. Overall survival				
Age	<70 vs. ≥ 70	0.832	0.565–1.224	0.3496
Gender	Female vs. Male	1.067	0.658–1.729	0.7936
Disease extent	LD vs. ED	1.131	0.673–1.901	0.6430
PS	0–1 vs. 2–4	1.588	1.047–2.407	0.0295 [*]
BCRP	(–) vs. (+)	1.235	0.831–1.833	0.2962

LD, limited disease; ED, extensive disease; PS, performance status; BCRP, breast cancer resistance protein.

^{*} $p < 0.05$.




Fig. 2. Progression-free survival curves (A) and overall survival curves (B) for 130 SCLC patients, according to breast cancer resistance protein (BCRP) expression.

cancer cell line MCF-7, and its overexpression was found to promote resistance to topoisomerase I inhibitors, including irinotecan and topotecan [17]. We previously reported the finding that BCRP expression is a significant predictor of survival in advanced NSCLC [18], but to our knowledge no data have been reported regarding BCRP expression in SCLC.

No significant association was found between the expression of other ABC transporter proteins and clinical outcome in the present study. Some studies have shown a relationship between expression of Pgp or MRP1 and response or survival [19–23], however, their clinical usefulness as therapeutic targets is still obscure. In fact, two randomized phase III studies that incorporated modulators of Pgp and one phase II study of VX-710, an inhibitor of both Pgp and MRP1, failed to show any survival benefit in SCLC patients [24–26].

In this study we also investigated the expression of the DNA excision repair proteins ERCC1 and BRCA1 in SCLC, but neither of them was related to response or survival. Expression of DNA excision repair proteins has hardly ever been investigated in SCLC, and to our knowledge there has been only one study in regard to it. In that study high expression of ERCC1 was associated with poor survival, but when the cases were grouped according to stage, a signifi-

cant decrease in survival was observed only in the LD patients, and the correlation between ERCC1 expression and response was not mentioned [27]. By contrast, expression of DNA excision repair proteins, especially ERCC1, has been intensively investigated in NSCLC recently, and expression of ERCC1 has been demonstrated to be related to platinum resistance in several studies [6,28,29]. We analyzed the ERCC1 expression also using the criterion by Olausson et al. [6], but the results were similar and our conclusions did not change (data not shown). BRCA1 expression was also demonstrated to be significantly associated with chemoresistance in one study [30]. However, in other studies no significant association was observed between expression of ERCC1 or BRCA1 and either response or survival [14,31]. Their clinical significance in lung cancer including SCLC has yet to be determined, and further studies are awaited.

The concept of "cancer stem cells", a very small fraction of the whole cell population repeating self-renewal continues to supply cancer-constitute cells, has recently gained wide acceptance. Although the origin of cancer stem cells has not yet been elucidated, the idea that malignant transformation of a normal stem cell has been proposed [32]. Side population (SP) cells, defined by Hoechst 33342 dye exclusion in flow cytometry, are considered to be an enriched source of normal stem cells [33]. In addition, BCRP has been shown to be a molecular determinant of the SP phenotype, and it can be used as a marker for stem cell selection [34]. In a recent study, SP cells isolated from lung cancer displayed elevated expression of BCRP and showed resistance to multiple chemotherapeutic agents [35]. These findings indicate that it may be possible to use BCRP as a marker of cancer stem cells in certain types of lung cancer.

In conclusion, the results of the present study indicated that immunohistochemical expression of BCRP is significantly associated with response and PFS in SCLC patients treated with platinum-based chemotherapy. Our results should be tested in LD patients who received thoracic radiotherapy, and it is also desirable that our results will be validated in other methods, such as mRNA expression analysis. Although confirmatory studies are needed, BCRP may be an ideal therapeutic target for SCLC. A variety of BCRP inhibitors have already been identified [36–39]. Clinical trials of combination of these agents with conventional chemotherapy might be acceptable in SCLC.

Conflict of interest statement

None declared.

Acknowledgements

This study was supported in part by a Grant-in-Aid for Third Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan.

References

- [1] Thatcher N, Faivre-Finn C, Lorigan P. Management of small-cell lung cancer. *Ann Oncol* 2005;16(Suppl 2):ii235–9.
- [2] Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. *Oncologist* 2003;8(5):411–24.
- [3] Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. *FEBS Lett* 2006;580(12):2903–9.
- [4] Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. *Nat Rev Drug Discov* 2006;5(3):219–34.
- [5] Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, et al. Applications of genomics in NSCLC. *Lung Cancer* 2005;50(Suppl 2):S33–40.
- [6] Olausson KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. *N Engl J Med* 2006;355(10):983–91.

- [7] Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. *Cancer Res* 2002;62(17):4899–902.
- [8] Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. *Br J Cancer* 2000;83(1):8–15.
- [9] Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Engl J Med* 2002;346(2):85–91.
- [10] Hanna N, Bunn Jr PA, Langer C, Einhorn L, Guthrie Jr T, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *J Clin Oncol* 2006;24(13):2038–43.
- [11] Zelen M. Keynote address on biostatistics and data retrieval. *Cancer Chemother Rep* 3 1973;4(2):31–42.
- [12] Therasse P, Arbuick SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000;92(3):205–16.
- [13] Filipits M, Haddad V, Schmid K, Huynh A, Dunanat A, André F, et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. *Clin Cancer Res* 2007;13(13):3892–8.
- [14] Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. *Lung Cancer* 2005;50(2):211–9.
- [15] Spiro SG, Silvestri GA. One hundred years of lung cancer. *Am J Respir Crit Care Med* 2005;172(5):523–9.
- [16] Haimeur A, Consell G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. *Curr Drug Metab* 2004;5(1):21–53.
- [17] Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). *Mol Cancer Ther* 2002;1(6):427–34.
- [18] Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. *Clin Cancer Res* 2004;10(5):1691–7.
- [19] Savaraj N, Wu CJ, Xu R, Lampidis T, Lai S, Donnelly E, et al. Multidrug-resistant gene expression in small-cell lung cancer. *Am J Clin Oncol* 1997;20(4):398–403.
- [20] Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. *Eur J Cancer* 1998;34(9):1352–7.
- [21] Hsia TC, Lin CC, Wang JJ, Ho ST, Kao A. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. *Lung* 2002;180(3):173–9.
- [22] Yeh JJ, Hsu NY, Hsu WH, Tsai CH, Lin CC, Liang JA. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. *Lung* 2005;183(3):177–83.
- [23] Triller N, Korosec P, Kern I, Kosnik M, Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naïve patients and in relapsed disease. *Lung Cancer* 2006;54(2):235–40.
- [24] Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. *Br J Cancer* 1993;68(4):813–8.
- [25] Wood L, Palmer M, Hewitt J, Urtasun R, Bruera E, Rapp E, et al. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. *Br J Cancer* 1998;77(4):627–31.
- [26] Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. *Cancer* 2007;109(5):924–32.
- [27] Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. *Lung Cancer* 2008;59(1):95–104.
- [28] Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. *Clin Cancer Res* 2002;8(7):2286–91.
- [29] Takenaka T, Yoshino I, Koush H, Ohba T, Yohena T, Osoegawa A, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. *Int J Cancer* 2007;121(4):895–900.
- [30] Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. *Hum Mol Genet* 2004;13(20):2443–9.
- [31] Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. *J Thorac Oncol* 2007;2(10):902–6.
- [32] Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. *Nat Rev Cancer* 2005;5(4):275–84.
- [33] Hadnagy A, Gaboury L, Beaulieu R, Ballicki D. SP analysis may be used to identify cancer stem cell populations. *Exp Cell Res* 2006;312(19):3701–10.
- [34] Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. *Aaps J* 2005;7(1):E118–33.
- [35] Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. *Cancer Res* 2007;67(10):4827–33.
- [36] Rabin dran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. *Cancer Res* 2000;60(1):47–50.
- [37] Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. *Cancer Res* 2004;64(4):1242–6.
- [38] Minderman H, O'Loughlin KL, Pendyala L, Baer MR. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. *Clin Cancer Res* 2004;10(5):1826–34.
- [39] Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. *Clin Cancer Res* 2005;11(6):2320–6.

Short Communication

Close Association of *UGT1A9* IVS1+399C>T with *UGT1A1**28, *6, or *60 Haplotype and Its Apparent Influence on 7-Ethyl-10-hydroxycamptothecin (SN-38) Glucuronidation in Japanese

Received August 26, 2008; accepted October 30, 2008

ABSTRACT:

The anticancer prodrug, irinotecan, is converted to its active form 7-ethyl-10-hydroxycamptothecin (SN-38) by carboxylesterases, and SN-38 is inactivated by UDP-glucuronosyltransferase (*UGT*)1A1-mediated glucuronidation. *UGT*1A9 also mediates this reaction. In a recent study, it was reported that the *UGT*1A9 IVS1+399 (I399)C>T polymorphism is associated with increased SN-38 glucuronidation both in vitro and in vivo. However, its role in *UGT*1A9 expression levels and activity is controversial. Thus, we evaluated the role of I399C>T in SN-38 glucuronidation using 177 Japanese cancer patients administered irinotecan. I399C>T was detected at a 0.636 allele frequency. This polymorphism was in strong linkage disequilibrium (LD) with *UGT*1A9*1b (-126_-118T₉>T₁₀, ID' = 0.99) and *UGT*1A1*6 (211G>A, 0.86), in moderate LD with *UGT*1A1*60 (-3279T>G, 0.55), but weakly

associated with *UGT*1A1*28 (-54_-39A(TA)₆TAA>A(TA)₇TAA, 0.25). Haplotype analysis showed that 98% of the I399C alleles were linked with low-activity haplotypes, either *UGT*1A1*6, *28, or *60. On the other hand, 85% of the T alleles were linked with the *UGT*1A1 wild-type haplotype *1. Although I399T-dependent increases in SN-38 glucuronide/SN-38 area under concentration-time curve (AUC) ratio (an in vivo marker for *UGT*1A activity) and decreases in SN-38 AUC/dose were apparent ($P < 0.0001$), these effects were no longer observed after stratified patients by *UGT*1A1*6, *28, or *60 haplotype. Thus, at least in Japanese populations, influence of I399C>T on SN-38 glucuronidation is attributable to its close association with either *UGT*1A1*6, *28, or *60.

Irinotecan is an important drug for treatment of various tumors including lung, colon, and gastric (Smith et al., 2006). The infused drug is metabolized to its active form 7-ethyl-10-hydroxycamptothecin (SN-38) by carboxylesterases, and SN-38 is inactivated by glucuronidation. At least four UDP-glucuronosyltransferase (*UGT*) isoforms, namely *UGT*1A1, *UGT*1A7, *UGT*1A9, and *UGT*1A10, are known to glucuronidate SN-38 (Gagné et al., 2002; Saito et al., 2007).

The *UGT*1A gene complex consists of 9 active first exons including *UGT*1A10, 1A9, 1A7, and 1A1 (in this order) and common exons 2 to 5. One of the 9 first exons can be used in conjunction with the common exons (Tukey and Strassburg, 2000). The *UGT*1A N-terminal domains (encoded by the first exons) determine substrate-binding specificity, and the C-terminal domain (encoded by exons 2 to 5) is important for binding to UDP-glucuronic acid. The 5'- or 3'-flanking region of each exon 1 is presumably involved in regulation of its expression. Substantial interindividual differences have been detected in mRNA and protein levels and enzymatic activity of the *UGT*1A isoforms (Fisher et al., 2000; Saito et al., 2007).

SN-38 glucuronidation is thought to be mediated mainly by *UGT*1A1,

This study was supported in part by the program for the Promotion of Fundamental Studies in Health Sciences from the National Institute of Biomedical Innovation [Grant 05-25]; and a Health and Labour Sciences Research grant from the Ministry of Health, Labour and Welfare in Japan [Grant KHB1008].

Y.S. and K.S. contributed equally to this work.

Article, publication date, and citation information can be found at <http://dmd.aspetjournals.org>.

doi:10.1124/dmd.108.024208

and its genetic polymorphisms affecting irinotecan pharmacokinetics and adverse reactions have been already identified. The TA-repeat polymorphism, -54_-39A(TA)₆TAA>A(TA)₇TAA (*UGT*1A1*28 allele), is associated with lower promoter activity, resulting in reduced SN-38 glucuronidation (Beutler et al., 1998; Iyer et al., 1999). The single nucleotide polymorphism (SNP) 211G>A (Gly71Arg, *6 allele), found mainly in East Asians, causes reduced protein expression levels and SN-38 glucuronidation activity (Gagné et al., 2002; Jinno et al., 2003). Another SNP in the enhancer region of *UGT*1A1, -3279T>G (*60 allele), is also a causative factor for reduced expression (Sugatani et al., 2002). Allele frequencies have been reported for *28 (0.09–0.13), *6 (0.15–0.19), and *60 (0.26–0.32) in Japanese and Chinese populations and for *28 (0.30–0.39), *6 (~0), and *60 (0.44–0.55) in whites (Saito et al., 2007). In a previous study, in the Japanese population, we defined haplotype *28 as the haplotype harboring the *28 allele, haplotype *6 as that harboring the *6 allele, and haplotype *60 as that harboring the *60 allele (and without the *28 or *6 allele) (Sai et al., 2004; Saeki et al., 2006). Note that most of the *28 haplotypes concurrently harbored the *60 alleles, and that the *28 and *6 alleles were exclusively present on the different chromosomes (Sai et al., 2004; Saeki et al., 2006). We have also revealed that the haplotype *28, *6, or *60 was associated with reduced SN-38 glucuronide (SN-38G)/SN-38 area under concentration-time curve (AUC) ratios, an in vivo parameter for *UGT*1A activity (Minami et al., 2007).

In a recent study, an intronic SNP of *UGT*1A9, IVS1+399 (I399)C>T, has been shown to be associated with increased *UGT*1A9 protein levels and glucuronidation activities toward SN-38 and the *UGT*1A9 probe drug propofol (Girard et al., 2006). Elevation of

ABBREVIATIONS: SN-38, 7-ethyl-10-hydroxycamptothecin; *UGT*, UDP-glucuronosyltransferase; SNP, single nucleotide polymorphism; SN-38G, SN-38 glucuronide; AUC, area under concentration-time curve; I399, *UGT*1A9 IVS1+399; LD, linkage disequilibrium.

SN-38 glucuronidation activity by this SNP is significant among subjects without *UGT1A1**28. Sandanaraj et al. (2008) have also reported that I399C/C patients showed higher SN-38 AUC than C/T and T/T patients. With the same *UGT1A1* diplotypes, patients with I399T/T (and *UGT1A9* -126_-118T₁₀/T₁₀) have shown higher SN-38G C_{max} than I399C/T (and T₁₀/T₁₀) patients. *UGT1A9**1*b* (*UGT1A9* -126_-118T₁₀>T₁₀) has been shown to have no effect on *UGT1A9* expression levels (Girard et al., 2006; Ramírez et al., 2007; Sandanaraj et al., 2008). Thus, two groups did suggest that I399T allele was associated with higher glucuronidation activity. However, using human liver microsomes, Ramírez et al. (2007) showed that I399C>T had no significant effect on both *UGT1A9* mRNA levels and glucuronidation activities for two *UGT1A9* substrates. Therefore, the roles of I399C>T in *UGT1A9* activities as well as SN-38 glucuronidation remain inconclusive.

In the present report, we reveal the linkage of I399C>T with *UGT1A1*, *UGT1A7*, and *UGT1A9* polymorphisms and analyze its association with the SN-38G/SN-38 AUC ratio and SN-38 AUC/dose (per dose) to clarify its role in SN-38 glucuronidation.

Materials and Methods

Patients. One hundred and seventy-seven patients (81 lung, 63 colon, 19 stomach, and 14 other cancer patients) administered irinotecan at the National Cancer Center were enrolled in this study as described previously (Minami et al., 2007). This study was approved by the ethics committees of the National Cancer Center and the National Institute of Health Sciences, and written informed consent was obtained from all participants. Eligibility criteria, patient profiles, and irinotecan regimens are summarized in our previous report (Minami et al., 2007). In brief, patients consisted of 135 males and 42 females with a mean age of 60.5 (26–78 years old), and their performance status was 0 (84 patients), 1 (89 patients), or 2 (4 patients). Irinotecan administrations were conducted according to the standard protocols in Japan as follows: i.v. 90-min infusion at a dose of 100 mg/m² weekly or 150 mg/m² biweekly in irinotecan monotherapy; and 60 mg/m² weekly with cisplatin in most combination therapies.

Genotyping and Haplotype Analysis. Genomic DNA was extracted from whole blood of 177 irinotecan-administered patients (Saeki et al., 2006). *UGT1A9* IVS1+399C>T (rs2741049) was genotyped using the TaqMan SNP Genotyping Assay Kit (C_9096281_10) according to the manufacturer's instructions (Applied Biosystems, Foster City, CA). The *UGT1A1**28 allele [-54_-39A(TA)₆TAA>A(TA)₇TAA], *UGT1A1**6 allele [211G>A (Cly71Arg)], *UGT1A1**60 allele (-3279T>G), *UGT1A7**2 haplotype [387T>G, 391C>A and 392G>A (Asn129Lys and Arg131Lys)], *UGT1A7**3 haplotype [387T>G, 391C>A, 392G>A, and 622T>C (Asn129Lys, Arg131Lys, and Tip208Arg)], and *UGT1A9**1*b* allele (-126_-118T₁₀>T₁₀) were determined previously (Saeki et al., 2006). Hardy-Weinberg equilibrium analysis of I399C>T, linkage disequilibrium (LD) analysis of the *UGT1A9*, *UGT1A7*, and *UGT1A1* polymorphisms, and haplotype estimation with an expectation-maximization algorithm were performed using SNPalyze version 7.0 software (Dynacom, Chiba, Japan).

Pharmacokinetics. Pharmacokinetic data for the 176 irinotecan-treated patients (data for one patient was unavailable) were described previously (Minami et al., 2007). In brief, heparinized blood was collected before irinotecan administration and at 0, 0.33, 1, 2, 4, 8, and 24 h after termination of the first infusion of irinotecan. SN-38 and SN-38G plasma concentrations were determined by high-performance liquid chromatography, and AUC was calculated using the trapezoidal method in WinNonlin version 4.01 (Pharsight, Mountain View, CA).

Statistical Analysis. Gene dose effects of I399C>T and *UGT1A1* haplotypes (*28, *6, or *60) were assessed by the Jonckheere-Terpstra test using StatExact version 6.0 (Cytel Inc., Cambridge, MA). Multiplicity adjustment was conducted with the false discovery rate. The significant difference was set at $p = 0.05$ (two-tailed).

Results

Linkages of *UGT1A9* IVS1+399 (I399)C>T with Other Polymorphisms. In our patients, I399C>T was detected at a 0.636 allele frequency, which is almost the same as those in the HapMap data (rs2741049) for Japanese (0.663) and Han Chinese (0.633) populations, but higher than those for Europeans (0.383) and Sub-Saharan Africans (Yoruba) (0.417). Genotype distribution for this SNP was in Hardy-Weinberg equilibrium ($p = 0.418$). LD analysis was performed between I399C>T and the previously determined genotypes, *UGT1A9**1*b*, *UGT1A7**2 and *3, and *UGT1A1**28, *6, and *60, which were detected at >0.1 frequencies in Japanese populations (Saeki et al., 2006). When assessed by the D' value, I399C>T was in complete LD with *UGT1A7* 387T>G, 391C>A and 392G>A (*UGT1A7**2, $D' = 1.000$); in strong LD with *UGT1A9* -126_-118T₁₀>T₁₀ (*UGT1A9**1*b*, 0.987), *UGT1A7* 622T>C (*UGT1A7**3, 0.977), and *UGT1A1* 211G>A (*UGT1A1**6, 0.864); and in moderate LD with *UGT1A1* -3279T>G (*UGT1A1**60, 0.554), but weakly associated with *UGT1A1* -54_-39A(TA)₆TAA>A(TA)₇TAA (*UGT1A1**28, 0.252). In r^2 values, the I399C>T was in strong LD with *UGT1A7**2 ($r^2 = 0.976$) and *UGT1A9**1*b* (0.916), in moderate LD with *UGT1A7**3 (0.478), but in weak LD with *UGT1A1**6 (0.261) and *UGT1A1**60 (0.208), and in little LD with *UGT1A1**28 (0.018).

Haplotype Analysis. Haplotype analysis was performed using the 9 polymorphisms including I399C>T. As shown in Fig. 1, 95% (123/129) of the I399C alleles were linked with the *UGT1A9* -126_-118T₁₀ alleles, and 100% (225/225) of the T alleles were linked with the T₁₀ alleles (*UGT1A9**1*b*). The I399C alleles were completely (129/129) linked with the *UGT1A7* 387G, 391A, and 392A alleles, and most T alleles (223/225) were linked with the 387T, 391C, and 392G alleles. The 40% (51/129) and 60% (78/129) of the I399C alleles were linked with *UGT1A7**2 and *UGT1A7**3 haplotypes, respectively. We also found that 98% (126/129) of the I399C alleles were linked with the *UGT1A1**6 (211G>A), *28 [-54_-39A(TA)₆TAA>A(TA)₇TAA], or *60 (-3279T>G). According to the *UGT1A1* haplotype definition by Sai et al. (2004), 42% (54/129), 36% (46/129), 19% (25/129), and 1% (1/129) of the I399C alleles were linked with the *UGT1A1* haplotypes *6*a* (harboring *6 allele), *60*a* (harboring *60 allele), *28*b* (harboring *60 and *28 alleles), and *28*d* (harboring *28 allele), respectively. On the other hand, 85% (191/225) of the T alleles were linked with the *UGT1A1* wild-type haplotype *1.

Association Analysis. The associations of I399C>T with irinotecan pharmacokinetic parameters were then analyzed using the estimated haplotypes. First, association with SN-38G/SN-38 AUC ratio, an in vivo parameter of *UGT1A* activity (Sai et al., 2004; Minami et al., 2007; Sandanaraj et al., 2008), was analyzed. *UGT1A7**2 had unchanged activity for SN-38 glucuronidation (Gagné et al., 2002), and neither *UGT1A9**1*b* nor *UGT1A7**3 had significant effects on the SN-38G/SN-38 AUC ratio in our previous study (Minami et al., 2007). On the other hand, the *UGT1A1**6, *28, and *60 haplotypes were associated with the reduced SN-38G/SN-38 AUC ratios (Minami et al., 2007). Although effects of the haplotype *28 and *6 were more striking, haplotype *UGT1A1**60, harboring only the *60 allele without the *28 allele, was weakly associated with the reduced ratio. To remove even this weak effect and clarify the real effect of I399C>T, *UGT1A1**60 was also considered as low-activity haplotype in this analysis. Namely, we analyzed the associations of I399C>T with the AUC ratio within the groups stratified by the *UGT1A1* haplotypes, *UGT1A1**28 (*28*b* and *28*d*), *6 (*6*a*), and *60 (*60*a*) (combined and shown as *UGT1A1*'+').

When stratified by the I399C>T genotype, a T allele-dependent

Gene		<i>UGT1A9</i>		<i>UGT1A7</i> ²				<i>UGT1A1</i> ³			Number	Frequency	
Nucleotide change		-126_- 118 T ₉ >T ₁₀	IVS1+ 399 C>T	387 T>G	391 C>A	392 G>A	622 T>C	-3279 T>G	(TA) ₆ > (TA) ₇	211 G>A			
Allele name		*1b		*2, *3	*2, *3	*2, *3	*3	*60, *28	*28	*6			
Haplotypes ¹	*1C- <i>*3</i> -*6a										47	0.133	
	*1C- <i>*2</i> -*60a										44	0.124	
	*1C- <i>*3</i> -*28b										21	0.059	
	*1C- <i>*2</i> -*28b										4	0.011	
	*1C- <i>*3</i> -*60a										2	0.006	
	*1C- <i>*3</i> -*28d										1	0.003	
	*1C- <i>*2</i> -*6a										1	0.003	
	*1bC- <i>*3</i> -*6a											6	0.017
	*1C- <i>*2</i> -*1											2	0.006
	*1C- <i>*3</i> -*1											1	0.003
	*1bT- <i>*1</i> -*1											190	0.537
	*1bT- <i>*3</i> -*1											1	0.003
	*1bT- <i>*1</i> -*28b											22	0.062
	*1bT- <i>*1</i> -*60a											5	0.014
	*1bT- <i>*1</i> -*6a											5	0.014
*1bT- <i>*1</i> -*28d											1	0.003	
*1bT- <i>*2</i> -*60a											1	0.003	
Allele frequency		0.653	0.636	0.370	0.370	0.370	0.223	0.280	0.138	0.167	354	1.000	

FIG. 1. Haplotypes assigned by using common *UGT1A9*, *UGT1A7*, and *UGT1A1* polymorphisms. ¹Haplotypes were shown as *UGT1A9* haplotypes - *UGT1A7* haplotypes - *UGT1A1* haplotypes. Major allele, white blocks; minor allele, gray blocks. *1C, T₉ and I399C; *1bC, T₁₀ and I399T in *UGT1A9*. ²*UGT1A7**2 and *3 are the haplotypes harboring the three and four *UGT1A7* alleles, respectively. ³*UGT1A1* (TA)₆>(TA)₇ indicates -54_-39A(TA)₆TAA>A(TA)₇TAA.

increase in the SN-38G/SN-38 AUC ratio was observed ($p < 0.0001$, Jonckheere-Terpstra test) (Fig. 2A). However, this trend was obviously dependent on biased distributions of *UGT1A1* haplotypes; e.g., 96% of the I399C/C patients were homozygotes for *UGT1A1**28, *6, or *60; and *UGT1A1**28, *6, or *60 (*UGT1A1*+) dependent reduction in the SN-38G/SN-38 ratio was found within the I399T/T genotypes ($p < 0.05$). As shown in Fig. 2B, *UGT1A1**28, *6, or *60 (*UGT1A1*+) dependent reduction in the SN-38G/SN-38 ratio was observed when patients were stratified by these three haplotypes. However, no significant effect of I399C>T was found within the stratified patients ($p > 0.05$ within the -/-, -/+, or +/+ patient group in Fig. 2B). As for SN-38 AUC/dose (SN-38 AUC values adjusted by the doses used), a similar *UGT1A1* haplotype dependence was observed. Although the I399T-dependent reduction of SN-38 AUC/dose was detected ($p < 0.0001$), biased distributions of the *UGT1A1**28, *6, or *60 were again evident, and the *UGT1A1* + haplotypes-dependent increase was significant within the I399 C/T and T/T patients ($p < 0.01$ and $p < 0.05$, respectively) (Fig. 2C). Moreover, no significant effect of I399C>T on SN-38 AUC/dose was found when stratified by the *UGT1A1* haplotypes ($p > 0.05$ within the -/-, -/+, or +/+ patient group in Fig. 2D).

Discussion

In the present study, LD between I399C>T and *UGT1A1*, *UGT1A7*, or *UGT1A9* polymorphisms in Japanese populations was shown for the first time. Moreover, the apparent effect of I399C>T on SN-38 glucuronidation in Japanese cancer patients was suggested to result from its close association with *UGT1A1**28, *6, or *60.

As for the influence of I399C>T on *UGT1A9* activity, conflicting results have been reported. Girard et al. (2006) have shown that I399C>T was associated with increased *UGT1A9* protein levels and enzyme activity toward an *UGT1A9* probe drug propofol using 48 human liver microsomes derived mainly from whites. In contrast, using human liver microsomes from 46 white subjects, Ramírez et al. (2007) have revealed that the I399C>T had no significant effects on *UGT1A9* mRNA levels and in vitro glucuronidation activities toward the two *UGT1A9* substrates, flavopiridol and mycophenolic acid. Furthermore, another report has demonstrated that I399C>T had no influence on the pharmacokinetic parameters (such as AUC and C_{max}) of mycophenolic acid in 80 Japanese renal transplant recipients (Inoue et al., 2007). Thus, these latter two studies did suggest that the I399C>T polymorphism has no effect on *UGT1A9* enzymatic activity. Note that, at least for Japanese populations, no study has reported that I399C>T affects *UGT1A9* activity.

As for the influence of I399C>T on SN-38 glucuronidation, a possible enhancing effect has been suggested. Girard et al. (2006) have shown an increasing effect of I399C>T on SN-38 glucuronidation, and that this SNP did not show any close linkages with the *UGT1A1**28 or *60 allele ($r^2 < 0.06$). In addition, Sandanaraj et al. (2008) have reported that in 45 Asians consisting of Chinese (80%), Malay (18%), and others (2%), I399C/C patients had higher SN-38 AUC than C/T and T/T patients. Again, this SNP was not in LD with the *UGT1A1**28, *6, or *60 allele (r^2 were < 0.09). Furthermore, association of I399T with increased SN-38G C_{max} has been observed even after stratified patients by *UGT1A1* genotypes, although the study sample size was small. These findings suggest that the I399T




FIG. 2. Association analysis of *UGT1A9* IVS1+399 (I399)C>T with SN-38G/SN-38 AUC ratio (A and B) and SN-38 AUC/dose (C and D). A and C. I399 C/C, C/T, and T/T patients were further divided by the presence of *UGT1A1**28, *6, or *60 haplotypes: -/-, no *UGT1A1**28, *6, or *60; +/-, heterozygotes for either *UGT1A1**28, *6, or *60; +/+, homozygotes or compound heterozygotes for either *UGT1A1**28, *6, or *60. B and D, *UGT1A1* -/-, +/-, and +/+ patients were further divided by I399 C/C, C/T, and T/T genotypes. Gene dose effects of I399C>T and the *UGT1A1* + haplotype were assessed by the Jonckheere-Terpstra test.

allele was associated with increased glucuronidation activity for SN-38 without linkages with the *UGT1A1* polymorphisms. Our data demonstrate that an increase in SN-38G/SN-38 AUC ratio (i.e., increased glucuronidation activity) was also found with I399C>T; however, after stratified patients by the *UGT1A1**6, *28, or *60 haplotypes (haplotype+) showing reduced SN-38 glucuronidation activity (Sai et al., 2004; Minami et al., 2007), any significant effect of the I399C>T was no longer observed. Thus, no direct effect of I399C>T on SN-38 glucuronidation was shown in the current study in Japanese populations. The discrepancy between our study and others might be derived from ethnic and/or population differences in haplotype distribution. In fact, in our Japanese population, 98% of the I399C alleles were linked with either *UGT1A1**6, *28, or *60, whereas 85% of the T alleles were linked with *UGT1A1**1. On the other hand, in Sandanaraj's report (in Chinese + Malay), 84% of the I399C alleles were linked with *UGT1A1**6, *28, or *60, whereas only 67% of the T alleles were linked with *UGT1A1**1 (Sandanaraj et al., 2008).

In irinotecan therapies, genetic polymorphisms leading to increases in SN-38 AUC, which closely correlates with increased

risk of severe neutropenia (Minami et al., 2007), are clinically important. The current study also demonstrated no significant influence of I399C>T on SN-38 AUC/dose after stratified patients by *UGT1A1* haplotypes. Consistent with this finding, no influence of this SNP was observed on the incidence of grade 3 or 4 neutropenia after irinotecan therapy in our population (data not shown). Recently, genetic testing of *UGT1A1**6 and *28, which are related to severe neutropenia in Japanese populations, has been approved for clinical application in Japan. This study indicates that there is no clinical necessity for additional genotyping of I399C>T, at least in Japanese populations.

In conclusion of this study, the apparent influence of I399 (*UGT1A9* IVS1+399)C>T on SN-38 glucuronidation is attributable to its close association with *UGT1A1**6, *28, or *60 in the Japanese population. Furthermore, additional genotyping of I399C>T for personalized irinotecan therapy seems to be clinically irrelevant for Japanese populations.

Acknowledgments. We thank Chie Sudo for secretarial assistance.